Reports Q2 revenue $119.0M, consensus $173.6M. “Our strong financial performance in the second quarter reflected consistent execution across all our growth drivers,” said Drew Hykes, CEO of Inari Medical. “We saw meaningful growth contributions from new product launches as well as international geographies, adding confidence to our 2023 outlook. We announced PEERLESS II, our third randomized controlled trial. These pivotal studies will elevate our therapies to the standard of care and reflect our unwavering commitment to VTE patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NARI:
- Inari Medical Reports Second Quarter 2023 Financial Results
- NARI Upcoming Earnings Report: What to Expect?
- Inari Medical to Present at the 43rd Annual Canaccord Growth Conference
- Inari Medical price target lowered to $65 from $70 at Truist
- Inari Medical initiated with an Outperform, $79 price target at Baird